Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push

Eitemau Tebyg

• Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
  gan: Graham Walter, et al.
  Cyhoeddwyd: (2020-05-01)
• Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
  gan: Walter, Graham, et al.
  Cyhoeddwyd: (2020)
• Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
  gan: Bienvenu, Boris, et al.
  Cyhoeddwyd: (2018)
• In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
  gan: Cozon, Grégoire Jacques Noël, et al.
  Cyhoeddwyd: (2018)
• Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study
  gan: Cowan, Juthaporn, et al.
  Cyhoeddwyd: (2020)